U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS
Key Takeaways from Analyst
The increasing prevalence rate of the disease is expected to be a major growth driver as it raises awareness and demand for effective treatment options. In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies.
In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies. This has expanded treatment choices for physicians and broadened the addressable patient pool.
High drug prices remain a restraint for market expansion as not all patients have adequate insurance coverage for the costly medications. This could limit their adoption. Nonetheless, pharmaceutical companies are making efforts to offer patient support programs to improve access.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
